(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603998 · · 13 pages · Chinese
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Iguratimod Tablets
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Cobamamide Capsules
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
Later from Hunan Fangsheng Pharmaceutical
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Outline of Q3 2026 Performance Briefing
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Change of Drug Manufacturing License
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice for Innovative TCM R&D Project
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Change of Drug Manufacturing License of Controlled Subsidiary
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical